Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released its financial results for the third quarter of 2024, alongside updates on its clinical trial programs. A key highlight includes …
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements Read More
LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) has reported a remarkable third quarter in 2024, achieving a record revenue of $2.94 million. This represents a 141% increase from the same …
NEXGEL Achieves Record Revenue in Q3 2024 with Promising Growth Outlook Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has released its financial results for the third quarter of 2024, reporting a revenue of $8.8 million, slightly down from $8.9 …
STRATA Skin Sciences Reports Q3 2024 Financial Results and Corporate Progress Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read MoreNEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) this week announced its third quarter financial results for 2024, alongside significant updates on its clinical programs. The company is …
Orchestra BioMed Reports Q3 2024 Results, Advances Key Clinical Programs Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has reported its financial and operational results for the third quarter of 2024, amid significant developments including the approval of its acquisition of …
Neuronetics Announces Q3 2024 Financial Results and Greenbrook TMS Acquisition Approval Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN) has released its financial results for the third quarter of 2024, revealing an increase in net revenue from its flagship product, XHANCE, and adjustments …
Optinose Reports Q3 2024 Financial Results, Highlights XHANCE Performance Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company …
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More
READING, PA — EnerSys (NYSE: ENS) announced its fiscal year 2025 second-quarter results, showcasing a gross margin improvement to 28.5%, a rise of 190 basis points from the previous year. …
EnerSys Reports Robust Second Quarter Fiscal 2025 Results Amid Strategic Progress Read More